The Company's distinguished Board of Directors is composed of seven members. Reappointment of Directors occurs on an annual basis by a plurality present or represented by proxy and entitled to vote at the annual meeting.
Mark A. Collar
Former President, P&G Pharmaceuticals and Personal Health
> Read Biography
Mark A. Collar is the owner of Collar, Ltd, his consulting and investment business. He is also a principal at Invisible Ink Tattoo Removers, the nation’s largest dedicated chain in this sector. Mr. Collar was previously President, Global Pharmaceuticals & Personal Health, a global division of the Procter & Gamble Company until he retired in 2008. Mr. Collar joined Procter & Gamble in 1975 as a Sales Representative before moving into Advertising Brand Management. Over the years, he held positions of increased responsibility within Health, Personal Care, and Beauty Care. Mr. Collar holds a Bachelor’s degree from Northern Illinois University. Mr. Collar currently serves as Chairman, Third Frontier Advisory Board (oversees this +$1 billion Ohio economic development investment fund), and is on the Boards of Atricure (ATRC), Enable Injections, Inc., and is Board Chair of the Fellowship of Catholic University Students.
Richard J. D'Augustine
Founding Board member, Ethicon EndoSurgery, Enable Medical and AtriCure
> Read Biography
Rick has over three decades of medical-industry experience in general management, venture capital investing and technology and business development in both public and private companies. He has served in a variety of C-Level capacities, including President & CEO, Chairman and Director of several private life-science companies. Previously, he spent five years as a group director at Senmed Medical Ventures, a private medical venture capital and business development firm.
D’Augustine spent 16 years with Johnson & Johnson and was a founding board member of Cincinnati-based Ethicon Endo-Surgery, initially serving as vice president of administration and CFO, and subsequently as vice president of business development. He was a founding board member of Enable Medical Corp., a private, high-technology medical device company, as well as Atricure Inc., an Enable spinoff focused on surgical treatment of atrial fibrillation, which is now a public company. Currently, Rick is an independent consultant focused on early stage companies and technologies, and serves as a director for Enable Injections, Inc. and Ischemia Care Diagnostics, LLC.
He has a bachelor’s of science degree in mechanical engineering from Rensselaer Polytechnic Institute and an MBA in finance from Seton Hall University.
Michael D. Hooven
CEO/Founder of Enable Injections, Enable Medical, and AtriCure
> Read Biography
Mike has over 30 years of experience in the medical device industry in a broad variety of technical and clinical areas. He is the founder of five medical device companies and holds over 100 issued and pending US patents.
Mike is the founder, and a Director of AtriCure, Inc. (Nasdaq ATRC). AtriCure is a Medical Device company that manufactures and sells surgical devices to treat the most serious forms of atrial fibrillation. AtriCure has grown rapidly to become the market leader, with over 200,000 procedures performed. AtriCure completed a successful Initial Public Offering on August 5, 2005, and currently trades on the NASDAQ under the symbol ATRC. Mike also is a Director and past Chairman of BioOhio, a state-funded organization to accelerate life-science start-up companies in Ohio. Mike was recently appointed by the Governor to the Third Frontier Advisory Board, a $2.3BB state funded initiative to accelerate high tech job creation in Ohio. Mike also sits on the Commercial Advisory Committee for the University of Cincinnati.
Mike previously held positions as the Chairman and CEO of AtriCure, and the Founder and Chairman of Enable Medical, a surgical device manufacturer that was acquired by AtriCure in August of 2005. Mike founded Enable in April of 1994, and prior to that he headed up all internal product development at Ethicon Endo-Surgery from 1988 to 1994. Mike held Engineering positions at Siemens/Pacesetter from 1986 to 1988, and at Cordis Corporation from 1981 to 1986. He earned a BS in Physics and a Master of Science in Mechanical Engineering from the University of Michigan.
Director of Life Sciences, CincyTech
> Read Biography
John Rice, director of life sciences at CincyTech, has 28 years of venture investing and 13 years of research and R&D management experience in biomedical science. He is a published scientist and inventor. Over the course of his career, John has been co-founder and Managing Partner of Triathlon Medical Ventures; a Managing Director of Senmed Medical Ventures, leading the emerging medical technology investment practice; and served in research, research management and business development roles with Battelle Memorial Institute. John serves on the Boards of Meridian Biosciences (VIVO), Eccrine Systems, Enable Injections, and is Chairman of Airway Therapeutics, Standard Bariatrics, Genetesis and Xact Medical. He has served previously on the boards of Akebia (AKBA) (Founder and Chairman), Aerpio (ARPO), Kereos, Syntherix (CEO), CS-Keys (interim CEO) and as an observer at Endocyte (ECYT) and CoLucid Pharmaceuticals (CLCD).
John is past chair of BioOhio and BioStart, Member of the Board of the Global Cardiovascular Innovation Center at the Cleveland Clinic, Chairman of the Investment Advisory Board of the Harrington Discovery Institute, Member of the Innovation Fund Advisory Board at Cincinnati Children’s Hospital Medical Center, and the Neuroinnovation Translator at Ohio State.
John earned his BS, MS and Ph.D. in microbiology and virology at Ohio State.
Senior Partner, ORI Capital
> Read Biography
Ms. Song is the Founding Partner of ORI Capital, a healthcare focused venture fund. She has more than 20 years of corporate finance experience. She was most recently a Managing Director in the Investment Banking Division of Goldman Sachs, responsible for its healthcare activities in Greater China and involved in a broad range of strategic advisory and financing transactions for healthcare clients. Prior to joining Goldman Sachs, she was a Managing Director of Cowen Group from January 2010 to September 2010. Ms. Song also served as a member of the advisory board of AXA Investment Managers from 2004 to 2010, and an executive board advisor to AXA Asia Pacific Holdings from 2004 to 2006. She received a BA in Economics from Fudan University and an MA in Economics from Claremont Graduate School.
Daniel Von Allmen M.D.
Chair of Pediatric Surgery For Childrens Hospital, Cincinnati
> Read Biography
Daniel von Allmen grew up outside of Philadelphia and attended Williams College followed by medical school at the University of Vermont College of Medicine. He then moved to Cincinnati for his General Surgery Residency which included 2 years in the laboratory of Dr. Josef Fischer studying sepsis and nutrition and a 2 year ECMO fellowship under the direction of Dr. Fred Ryckman. Upon completion of his general surgery training, he stayed in Cincinnati for Pediatric Surgery training. Dr. von Allmen moved to the Children’s Hospital of Philadelphia in 1997 where he developed a strong clinical focus on oncology, inflammatory bowel disease, robotics and minimally invasive surgery. He remains an active participant in both the Children’s Oncology group and the Crohn’s & Colitis Foundation of America. In 2003 he returned to UNC to assume the role of Division Director and Surgeon-in-Chief at the newly constructed North Carolina Children’s Hospital. During that time he established research relationships with the biomedical engineering group at Duke University studying image guided surgery and with the mechanical engineering group at NC State developing robotics applications in surgery. In 2009 he returned to Cincinnati to become the Director of General and Thoracic Surgery and Program Director for the Surgical Residency at the Cincinnati Children’s Hospital Medical Center. In 2013 the Cincinnati Esophageal Center was begun and he is the Director of that Center. In 2015, he became Surgeon-in-Chief of the Cincinnati Children’s Hospital Medical Center. He has an active interest in surgical innovation with a funded international project on robotics and image guided surgery along with other projects both locally and internationally.
Norman R. Weldon, Ph.D.
Founder / CEO / Investor in over 20 successful medical device companies
> Read Biography
Norm Weldon's background is in economics, technology and general management. He has been the CEO of three public companies: CTS Corporation (NYSE CTS), Cordis Corporation (NASDAQ CORD) and Corvita Corporation (NASDAQ CVTA). He has been a co-founder of CTS Microelectronics, Inc., Corvita Corporation, Novoste Puerto Rico, Inc., Novoste Corporation, Enable Medical Corporation, AtriCure, Inc., Medivance, Inc., Neuronetics, Inc. and Ponce de Leon, DAC. Via Partisan Management Group, Inc., and/or Weldon Foundation, Inc. Norm has additionally been a seed and early stage investor in HemoCleanse, Inc., Ash Access, Inc., Symbiosis Corporation, Impla-Med, Inc., RxKinetics, Inc., Renal Solutions, Inc., ZS Pharma, Inc., Preceptis Medical, Inc., Surefire Medical, Inc. and Enable Injections, Inc.
Partisan Management Group, Inc. has returned cash on cash results of 6.5 times invested capital over 12 completed investments. Partisan has six current portfolio companies ranging from late stage Neuronetics, Inc. to early stage Ponce de Leon, DAC. Partisan has also been a limited partner in seven other venture funds.
Norm has degrees in biochemistry, business and a PhD in Economics, all from Purdue University. Norm Weldon and Tom Weldon played roles in the founding and development of what is now known as the Weldon School of Biomedical Engineering at Purdue. Norm and Tom have had three billion dollar plus exits in the last two years:
Norm: ZS Pharmaceuticals $2.7 billion via sale to AstraZeneca
Tom: Nevro $2.4 billion via IPO
Tom: Inogen $1.9 billion via IPO